PLYX — Polaryx Therapeutics, Cashflow Statement
0.000.00%
Last trade - 00:00- $268.91m
- $263.16m
Annual cashflow statement for Polaryx Therapeutics,, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -3.78 | -30.4 |
| Non-Cash Items | 3.24 | 28.4 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | 0.369 | -0.621 |
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Cash from Operating Activities | -0.173 | -2.57 |
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 0.128 | 7.19 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -0.045 | 4.62 |